What’s next for molecular diagnostics and precision medicine?

Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.

Cognigenics is using advanced gene-editing techniques to develop intranasal treatments that target neural networks associated with anxiety and memory disorders, which could yield long-term solutions.

CRISPR QC’s chip platform-enabling efficiency that aims to power the next generation of CRISPR therapies.

Combining first-in-class delivery and engineering tools, Ensoma is developing one-time in vivo treatments that can precisely engineer any cell of the blood and immune systems to cure diseases from within.

Venture-backed start-up MeCo Diagnostics has developed a first-in-class, clinically validated, prognostic and predictive biomarker test to enable targeted antifibrotic therapy for early-stage breast cancer patients.

Screening and diagnostics based on the detection of cancer-generated cellular biomarkers.